Surgery Partners' stock experienced a significant 24.37% plunge during intraday and after-hours trading, following the release of its fourth quarter 2025 financial results.

The sharp decline was primarily driven by a substantial earnings miss, with Q4 adjusted EPS of $0.12 falling 60% short of the analyst consensus estimate of $0.30. Furthermore, the company reported Q4 adjusted EBITDA of $156.9 million, which missed estimates of $169.2 million, indicating significant margin pressure that impacted full-year performance according to company statements.

Adding to investor concerns, Surgery Partners provided 2026 revenue guidance in the range of $3.35 billion to $3.45 billion, which came in below the consensus estimate of $3.56 billion. While the company announced a $200 million share repurchase program and reported Q4 revenue of $885 million that beat estimates, the profitability shortfalls and cautious outlook overshadowed these positive developments.